Antiviral activities of 9-R-2-phosphonomethoxypropyl adenine (PMPA) and bis(isopropyloxymethylcarbonyl)PMPA against various drug-resistant human immunodeficiency virus strains

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 6, 1998, Pages 1484-1487

  Srinivas, Ranga V ^a,c   Fridland, Arnold ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c SJCRH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIS(ISOPROPYLOXYMETHYLCARBONYL)PHOSPHONOMETHOXYPROPYL ADENINE; DIDANOSINE; LAMIVUDINE; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; VIRUS RESISTANCE;

EID: 0031861195     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.6.1484     Document Type: Article

References (41)

1. Armilli, M. N., C. U. Kim, J. Dougherty, A. Mulato, R. Oliyai, J. P. Shaw, K. C. Cundy, and N. Bischofberger. 1997. Synthesis, in vitro evaluation and oral bioavailability of [9-(2-phosphonylmethoxyethyl)adenine prodrugs. Antivir. Chem. Chemother. 8:557-564.
2. Balzarini, J., and E. De Clercq. 1995. Acyclic purine nucleoside phosphonates as retrovirus inhibitors, p. 41-45. In D. J. Jeffries and E. De Clercq (ed.), Antiviral chemotherapy. John Wiley & Sons, Inc., New York, N.Y.
3. Bischofberger, N., L. Naesens, E. De Clercq, A. Fridland, R. V. Srinivas, B. L. Robbins, M. Arimilli, K. Cundy, C. Kim, S. Lacy, W. Lee, and J. Shaw. 1997. Bis(POC)PMPA, an orally bioavailable prodrug of the antiretroviral agent PMPA, abstr. 214, p. 104. In Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections.
4. Carpenter, C. C., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1997. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA Panel. JAMA 277:1962-1969.
5. Cherrington, J. M., K. K. A. Van Rompay, A. S. Multao, M. L. Marthas, C. J. Berardi, S. Telm, N. Bischofberger, and N. C. Pedersen. 1996. Phenotypic and genotypic characterization of simian immunodeficiency viruses (SIV) with reduced susceptibility to PMPA isolated after PMPA therapy, abstr. 75. In Program and abstracts of Fifth International Workshop on HIV Drug Resistance.
6. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995). In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571.
7. Deeks, S. G., P. Barditch-Grovo, P. Lietman, F. Hwang, K. Cundy, J. Rooney, N. Nellman, and J. Khan. Unpublished data.
8. Fiers, W., R. Contreras, F. Duerinck, G. Haegeman, D. Iserentant, J. Merregaert, W. Min Jou, F. Molemans, A. Raeymaekers, A. Van den Berghe, G. Volckaert, and M. Ysebaert. 1976. Complete nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the replicase gene. Nature 260:500-507.
9. Fitzgibbon, J. E., F.-M. Howell, C. A. Haberzettl, S. J. Sperber, D. J. Gockle, and D. T. Dubin. 1992. Human immunodeficiency virus type I pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob. Agents Chemother. 36:153-157.
10. Foli, A., K. M. Sogocio, B. Anderson, M. Kavlick, M. W. Saville, M. A. Wainberg, Z. Gu, J. M. Cherrington, H. Mitsuya, and R. Yarchoan. 1996. In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA). Antivir. Res. 32:91-98.
11. Fridland, A., B. L. Robbins, R. V. Srinivas, M. Armili, C. Kim, and N. Bischofberger. 1997. Antiretroviral activity and metabolism of bis(poc) PMPA, an oral prodrug of PMPA, abstr. 27, p. A49. In Program and abstracts of the Tenth International Conference on Antiviral Research.
12. Gu, Z., Q. Gao, X. Li, M. A. Parniak, and M. A. Wainberg. 1994. Identification of a mutation at codon 65 in the IKKF motif reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38:275-281.
13. Gu, Z., E. J. Arts, M. A. Parniak, and M. A. Wainberg. 1995. Mutated K65R recombinant reverse transcriptase of human immunodeficiency virus type 1 shows diminished chain termination in the presence of 2′,3′-dideoxycytidine 5′-triphosphate and other drugs. Proc. Natl. Acad. Sci. USA 92:2760-2764.
14. Gu, Z., H. Salomon, J. Cherrington, A. S. Mulato, M. S. Chen, R. Yarchoan, A. Foli, K. M. Sogocio, and M. A. Wainberg. 1995. K65R mutation of human immunodeficiency virus type 1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother 39:1888-1891.
15. Holodniy, M., L. Mole, D. Margolis, J. Moss, H. Dong, E. Boyer, M. Urdea, J. Kolberg, and S. Eastman. 1995. Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosinc combination therapy. J. Virol. 69:3510-3516.
16. Jacobsen, H., K. Yasargil, D. L. Winslow, J. C. Craig, A. Kröhn, I. B. Duncan, and J. Mous. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527-534.
17. Kellam, P., C. A. Boucher, and B. A. Larder. 1992. Fifth mutation in human immunodeficiency virus type I reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89:1934-1938.
18. Larder, B. A., and S. D. Kemp. 1989. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246: 1155-1158.
19. Larder, B. A., G. Darby, and D. D. Richman. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243:1731-1734.
20. Larder, B. A., P. Kellam, and S. D. Kemp. 1993. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365:451-453.
21. Naesens, L., N. Bischofberger, M. Arimili, C. Kim, and E. De Clercq. 1997. Antiretrovirus activity and pharmacokinetics in mice of bis(poc)PMPA, the bis(isopropyloxycarbonyloxymethyl) oral prodrug of PMPA, abstr. 28, p. A50. In Abstracts of the Tenth International Conference on Antiviral Research.
22. Nunberg, J. H., W. A. Schleif, E. J. Boots, J. A. O'Brien, J. C. Quintero, J. M. Hoffman, E. A. Emini, and M. E. Goldman. 1991. Viral resistance to human immunodeficiency virus type 1-specific pyridinone reverse transcriptase inhibitors. J. Virol. 65:4887-4892.
23. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C. K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type I selected during therapy. J. Virol. 68:1660-1666.
24. Robbins, B., R. V. Srinivas, C. Kim, N. Bischofberger, and A. Fridland. Anti-human immunodeficiency virus activity and cellular metabolism of a potential prodrug of the acyclic nucleoside phosphonate 9-R-(2-phosphonomethoxypropyl)adenine (PMPA), bis(isopropyloxymethylcarbonyl) PMPA. Antimicrob. Agents Chemother. 42:612-617.
25. Schinazi, R. F., R. M. Lloyd, Jr., M. H. Nguyen, D. L. Cannon, A. McMillan, N. Ilksoy, C. K. Chu, D. C. Liotta, H. Z. Bazmi, and J. W. Mellors. 1993. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. 37:875-881.
26. Schinazi, R. F., B. A. Larder, and J. W. Mellors. 1996. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 4:95-107.
27. Shafer, R. W., M. J. Kozal, M. A. Winters, A. K. Iversen, D. A. Katzenstein, M. V. Ragni, W. A. Meyer 3rd, P. Gupta, S. Rasheed, R. Coombs, et al. 1994. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. 169:722-729.
28. Shirasaka, T., M. F. Kavlick, T. Ueno, W. Y. Gao, E. Kojima, M. L. Alcaide, S. Chokekijchai, B. M. Roy, E. Arnold, R. Yarchoan, and H. Mitsuya. 1995. Emergence of human immunodeficiency virus type I variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Natl. Acad. Sci. USA 92:1-5.
29. 28a. Srinivas, R. V. Unpublished results.
30. Srinivas, R. V. and J. L. Hurwitz. 1997. HIV growth, inhibition and measurement, p. 1959-1973. In I. Lefkowitz (ed.), The immunology methods manual. Academic Press, Inc., New York, N.Y.
31. Srinivas, R. V., B. L. Robbins, M. Connelly, Y.-F. Gong, N. Bischoffberger, and A. Fridland. 1993. Metabolism and in vitro antiretroviral activities of bis(pivaloyloxymethyl) prodrugs of acyclic nucleoside phosphonates. Antimicrob. Agents Chemother. 37:2247-2250.
32. St. Clair, M. H., J. L. Martin, G. Tudor-Williams, M. C. Bach, C. L. Vavro, D. M. King, P. Kellam, S. D. Kemp, and B. A. Larder. 1991. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253:1557-1559.
33. Sylvester, S., A. Caliendo, K. Sepkowitz, M. Fischl, D. Jayaweera, G. Simon, J. Lalezari, R. Mitsuyas, and R. D'Aquila. 1996. HIV-1 resistance mutations and plasma RNA levels during ZDV + ddC combination therapy, abstr. 107. In Program and abstracts of the 3rd Conference on Retrovioruses and Opportunistic Infections.
34. Tanaka, M., R. V. Srinivas, T. Ueno, M. F. Kavlick, F. K. Hui, A. Fridland, J. S. Driscoll, and H. Mitsuya. 1997. In vitro induction of human immunodeficiency virus type 1 variants resistant to 2′-β-fluoro-2′,3′-dideoxyadenosine. Antimicrob. Agents Chemother. 41:1313-1318.
35. Tisdale, M., N. R. Parry, D. Cousens, M. H. St. Clair, and L. R. Boone. 1996. Anti-HIV activity of (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2cyclopentene-1-methanol (1592U89), abstr. 182, p. 92. In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
36. Tsai, C. C., K. E. Follis, T. W. Beck, A. Sabo, N. Bischofberger, and P. J. Dailey. 1997. Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques. AIDS Res. Hum. Retroviruses 13:707-712.
37. Tsai, C. C., K. E. Follis, A. Sabo, T. W. Beck, R. F. Grant, N. Bischofberger, R. E. Benveniste, and R. Black. 1995. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl) adenine. Science 270:1197-1199.
38. Ueno, T., T. Shirasaka, and H. Mitsuya. 1995. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J. Biol. Chem. 270:23605-23611.
39. Van Rompay, K. K. A., J. M. Cherrington, M. L. Marthas, C. J. Berardi, A. S. Mulato, A. Spinner, R. P. Tarara, D. R. Canfield, S. Telm, N. Bischofberger, and N. C. Pedersen. 1996. PMPA therapy of established SIV infection of infant rhesus macaques. Antimicrob. Agents Chemother. 40:2586-2591.
40. Winters, M. A., R. W. Shafer, R. A. Jellinger, G. Mamtora, T. Gingeras, and T. C. Merigan. 1997. Human immunodeficiency virus type 1 reverse transcriptase genotype and drug susceptibility changes in infected individuals receiving dideoxyinosine monotherapy for 1 to 2 years. Antimicrob. Agents Chemother. 41:757-762.
41. Zhang, D., A. M. Caliendo, J. J. Eton, K. M. DeVore, J. C. Kaplan, M. S. Hirsch, and R. T. D'Aquila. 1994. Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type I reverse transcriptase. Antimicrob. Agents Chemother. 38:282-287.